	US 12,378,604 B2
	Alpha-hemolysin variants and uses thereof
Timothy K. Craig, Campbell, CA (US); Mark R. Ambroso, San Jose, CA (US); Corissa J. Harris, Santa Clara, CA (US); Matthew M. Dipietro, Gilroy, CA (US); Yaozhong Zou, Sunnyvale, CA (US); and Marshall W. Porter, Santa Clara, CA (US)
Assigned to Roche Sequencing Solutions, Inc., Pleasanton, CA (US)
Filed by Roche Sequencing Solutions, Inc., Pleasanton, CA (US)
Filed on Feb. 25, 2021, as Appl. No. 17/185,021.
Application 17/185,021 is a continuation of application No. 16/425,743, filed on May 29, 2019, granted, now 10,968,480.
Application 16/425,743 is a continuation of application No. 15/492,214, filed on Apr. 20, 2017, granted, now 10,351,908, issued on Jul. 16, 2019.
Claims priority of provisional application 62/325,749, filed on Apr. 21, 2016.
Prior Publication US 2021/0269870 A1, Sep. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6869 (2018.01); C07K 14/31 (2006.01); C12Q 1/689 (2018.01); G01N 27/447 (2006.01); G01N 33/487 (2006.01)

CPC C12Q 1/6869 (2013.01) [C07K 14/31 (2013.01); C12Q 1/689 (2013.01); G01N 27/44791 (2013.01); G01N 33/48721 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/31 (2013.01)]

24 Claims

1. An alpha-hemolysin variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 14, wherein said amino acid sequence comprises (i) an H35 substitution of SEQ ID NO: 14 and (ii) a positively charged amino acid substituted for one or more positions of SEQ ID NO: 14 selected from the group consisting of T109, V149, P151, and E287 of SEQ ID NO: 14.